FindTrial
Sign In

Cost-effectiveness of anti tuberculosis medicines (Bedaquiline, Delamanid, Linezolid and combination) based on Quality-Adjusted Life-Years (QALYs) versus Disability-Adjusted Life-Years (DALYs)

Comparing the cost-effectiveness of bedaquiline, delamanid, linezolid and their combinations based on Quality-Adjusted Life-Years (QALYs) versus Disability-Adjusted Life-Years (DALYs) in patients with multidrug-resistant and extended drug-resistant tuberculosis at tertiary care hospital in South Gujarat - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/08/071882
Enrollment
300
Registered
2024-08-05
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Z870- Personal history of diseases of the respiratory system

Interventions

Intervention1: NIL: NIL

Sponsors

Shah Paras Jagdishkumar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Data of adult (â?¥18 years of age) MDR or XDR-TB patients of either gender on Bedaquiline/Delamanid/Linezolid/Combinations.

Exclusion criteria

Exclusion criteria: 1) Data containing inadequate details 2) Anti-Retroviral Therapy in addition to data meeting inclusion criteria

Design outcomes

Primary

MeasureTime frame
1) Cost-effectiveness of bedaquiline (Bdq), delamanid (Dlm), linezolid (Lzd) and their combinations based on QALYs versus DALYs 2) Other pharmacoeconomic variables like cost-utility, cost-benefit and cost-minimizationTimepoint: 1 year—

Secondary

MeasureTime frame
Correlation of demographic data like socioeconomic status, area, gender and resistance pattern of anti-TB drugsTimepoint: 1 year—

Countries

India

Contacts

Public ContactShah Paras Jagdishkumar

Government Medical College, Surat

drchetnapatel2012@yahoo.com7990618600

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026